BIOMAT Database Logo BIOMAT Database Logo

Reduced-intensity conditioning followed by allogeneic transplantation in pediatric malignancies: a report from the Société Française des Cancers de l'Enfant and the Société Française de Greffe de Moelle et de Thérapie Cellulaire. 2013

C Paillard, and E Rochette, and P Lutz, and Y Bertrand, and G Michel, and P Bordigoni, and J H Dalle, and P Rohrlich, and J P Vannier, and Y Perel, and D Plantaz, and G Leverger, and A Sirvent, and E Dore, and F Isfan, and E Merlin, and B Pereira, and P Halle, and N Rabiau, and J Kanold, and F Deméocq
CHU Clermont-Ferrand, Centre Régional de Cancérologie et Thérapie Cellulaire Pédiatrique, Clermont-Ferrand, France.

We report French prospective experience with reduced-intensity conditioning-allo-SCT in 46 patients (median age: 15.5 years, 4.8-20.2) presenting high-risk AL (n=11), Hodgkin's lymphoma (n=15) or solid tumors (n=20). Graft sources were BM (n=21), PBSC (n=20) and cord blood (CB; n=5) from related (n=20) or unrelated (n=26) donors. For CB grafts, only one patient out of five achieved sustained engraftment. For PBSC/BM grafts, engraftment rate was 95%, hematopoietic recovery times were not significantly different between BM, PBSC, sibling or unrelated grafts, day+100. Full donor chimerism was achieved in 94% of patients, and incidences of primary acute GVHD and chronic GVHD were 49% and 14%, respectively. Underlying disease was fatal in 39% of patients. TRM was 6.9%. Three-year OS was 49.15%. OS and EFS were not significantly different between patients transplanted with different grafts and with or without primary GVHD. Patients with solid tumor or measurable disease at transplant had poorer outcomes. Three-year EFS: 33.3% for ALL, 75.0% for AML, 51.8% for Hodgkin's lymphoma, 28.6% for neuroblastoma and 22.2% for sarcoma patients. This multicentre study concluded that Bu/fludarabine/anti-thymocyte globulin conditioning with PB or BM, related or unrelated grafts in patients with various malignancies at high-risk for transplantation toxicity results in high engraftment rates, low TRM and acceptable survival.

UI MeSH Term Description Entries
D008297 Male Males
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D005602 France A country in western Europe bordered by the Atlantic Ocean, the English Channel, the Mediterranean Sea, and the countries of Belgium, Germany, Italy, Spain, Switzerland, the principalities of Andorra and Monaco, and by the duchy of Luxembourg. Its capital is Paris. Corsica,Saint Pierre and Miquelon,Miquelon and Saint Pierre,Miquelon and St. Pierre,St. Pierre and Miquelon
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

C Paillard, and E Rochette, and P Lutz, and Y Bertrand, and G Michel, and P Bordigoni, and J H Dalle, and P Rohrlich, and J P Vannier, and Y Perel, and D Plantaz, and G Leverger, and A Sirvent, and E Dore, and F Isfan, and E Merlin, and B Pereira, and P Halle, and N Rabiau, and J Kanold, and F Deméocq
Upfront allogeneic stem cell transplantation after reduced-intensity/nonmyeloablative conditioning for patients with myelodysplastic syndrome: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
September 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,
C Paillard, and E Rochette, and P Lutz, and Y Bertrand, and G Michel, and P Bordigoni, and J H Dalle, and P Rohrlich, and J P Vannier, and Y Perel, and D Plantaz, and G Leverger, and A Sirvent, and E Dore, and F Isfan, and E Merlin, and B Pereira, and P Halle, and N Rabiau, and J Kanold, and F Deméocq
Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
February 2011, British journal of haematology,
C Paillard, and E Rochette, and P Lutz, and Y Bertrand, and G Michel, and P Bordigoni, and J H Dalle, and P Rohrlich, and J P Vannier, and Y Perel, and D Plantaz, and G Leverger, and A Sirvent, and E Dore, and F Isfan, and E Merlin, and B Pereira, and P Halle, and N Rabiau, and J Kanold, and F Deméocq
Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
May 2008, Experimental hematology,
C Paillard, and E Rochette, and P Lutz, and Y Bertrand, and G Michel, and P Bordigoni, and J H Dalle, and P Rohrlich, and J P Vannier, and Y Perel, and D Plantaz, and G Leverger, and A Sirvent, and E Dore, and F Isfan, and E Merlin, and B Pereira, and P Halle, and N Rabiau, and J Kanold, and F Deméocq
Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
November 2003, Bone marrow transplantation,
C Paillard, and E Rochette, and P Lutz, and Y Bertrand, and G Michel, and P Bordigoni, and J H Dalle, and P Rohrlich, and J P Vannier, and Y Perel, and D Plantaz, and G Leverger, and A Sirvent, and E Dore, and F Isfan, and E Merlin, and B Pereira, and P Halle, and N Rabiau, and J Kanold, and F Deméocq
Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
October 2011, Haematologica,
C Paillard, and E Rochette, and P Lutz, and Y Bertrand, and G Michel, and P Bordigoni, and J H Dalle, and P Rohrlich, and J P Vannier, and Y Perel, and D Plantaz, and G Leverger, and A Sirvent, and E Dore, and F Isfan, and E Merlin, and B Pereira, and P Halle, and N Rabiau, and J Kanold, and F Deméocq
Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies.
December 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
C Paillard, and E Rochette, and P Lutz, and Y Bertrand, and G Michel, and P Bordigoni, and J H Dalle, and P Rohrlich, and J P Vannier, and Y Perel, and D Plantaz, and G Leverger, and A Sirvent, and E Dore, and F Isfan, and E Merlin, and B Pereira, and P Halle, and N Rabiau, and J Kanold, and F Deméocq
Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A Retrospective Study of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
August 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,
C Paillard, and E Rochette, and P Lutz, and Y Bertrand, and G Michel, and P Bordigoni, and J H Dalle, and P Rohrlich, and J P Vannier, and Y Perel, and D Plantaz, and G Leverger, and A Sirvent, and E Dore, and F Isfan, and E Merlin, and B Pereira, and P Halle, and N Rabiau, and J Kanold, and F Deméocq
Treatment of adult ALL with central nervous system involvement at diagnosis using autologous and allogeneic transplantation: a study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
May 2013, Bone marrow transplantation,
C Paillard, and E Rochette, and P Lutz, and Y Bertrand, and G Michel, and P Bordigoni, and J H Dalle, and P Rohrlich, and J P Vannier, and Y Perel, and D Plantaz, and G Leverger, and A Sirvent, and E Dore, and F Isfan, and E Merlin, and B Pereira, and P Halle, and N Rabiau, and J Kanold, and F Deméocq
Pre-transplantation risk factors to develop sclerotic chronic GvHD after allogeneic HSCT: a multicenter retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
February 2015, Bone marrow transplantation,
C Paillard, and E Rochette, and P Lutz, and Y Bertrand, and G Michel, and P Bordigoni, and J H Dalle, and P Rohrlich, and J P Vannier, and Y Perel, and D Plantaz, and G Leverger, and A Sirvent, and E Dore, and F Isfan, and E Merlin, and B Pereira, and P Halle, and N Rabiau, and J Kanold, and F Deméocq
Pulmonary Alveolar Proteinosis After Allogeneic Hematopoietic Stem-Cell Transplantation in Adults: A French Société Francophone de Greffe de Moelle et Thérapie Cellulaire Survey.
November 2021, Chest,
Copied contents to your clipboard!